Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4939)
All Articles published online
|
Oct 14, 2012 (publication date) through Dec 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jiao ZJ, Gao JJ, Hua SH, Chen DY, Wang WH, Wang H, Wang XH, Xu HX. Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer. World J Gastroenterol 2012; 18(38): 5454-5461 [PMID: 23082063 DOI: 10.3748/wjg.v18.i38.5454] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v18/i38/5454.htm |
| Number | Citing Articles |
| 1 |
Ajaz A. Bhat, Sabah Nisar, Selma Maacha, Tatiana Correa Carneiro-Lobo, Sabah Akhtar, Kodappully Sivaraman Siveen, Nissar A. Wani, Arshi Rizwan, Puneet Bagga, Mayank Singh, Ravinder Reddy, Shahab Uddin, Jean-Charles Grivel, Gyan Chand, Michael P. Frenneaux, Mushtaq A. Siddiqi, Davide Bedognetti, Wael El-Rifai, Muzafar A. Macha, Mohammad Haris. Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Molecular Cancer 2021; 20(1) doi: 10.1186/s12943-020-01294-3
|
| 2 |
K. Gabrusiewicz, N.A. Colwell, A.B. Heimberger. Translational Immunotherapy of Brain Tumors. 2017; : 63 doi: 10.1016/B978-0-12-802420-1.00004-1
|
| 3 |
Karolina Okla, Iwona Wertel, Anna Wawruszak, Marcin Bobiński, Jan Kotarski. Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells – is a new era coming?. Critical Reviews in Clinical Laboratory Sciences 2018; 55(6): 376 doi: 10.1080/10408363.2018.1477729
|
| 4 |
Kiran H. Lagisetty, Dyke P. McEwen, Derek J. Nancarrow, Johnathon G. Schiebel, Daysha Ferrer-Torres, Dipankar Ray, Timothy L. Frankel, Jules Lin, Andrew C. Chang, Laura A. Kresty, David G. Beer. Immune determinants of Barrett’s progression to esophageal adenocarcinoma. JCI Insight 2021; 6(1) doi: 10.1172/jci.insight.143888
|
| 5 |
Ruoting Zheng, Shiyi Chen, Shenren Chen. Correlation between myeloid-derived suppressor cells and S100A8/A9 in tumor and autoimmune diseases. International Immunopharmacology 2015; 29(2): 919 doi: 10.1016/j.intimp.2015.10.014
|
| 6 |
Liang Wen, Ping Gong, Chao Liang, Dawei Shou, Baoqing Liu, Yiwen Chen, Changqian Bao, Li Chen, Xiaowei Liu, Tingbo Liang, Weihua Gong. Interplay between myeloid-derived suppressor cells (MDSCs) and Th17 cells: foe or friend?. Oncotarget 2016; 7(23): 35490 doi: 10.18632/oncotarget.8204
|
| 7 |
Maham Farshidpour, Monjur Ahmed, Shilpa Junna, Juanita L Merchant. Myeloid-derived suppressor cells in gastrointestinal cancers: A systemic review. World Journal of Gastrointestinal Oncology 2021; 13(1): 1-11 doi: 10.4251/wjgo.v13.i1.1
|
| 8 |
Hiroshi Katoh. Systemic Drug Delivery Strategies. 2022; : 409 doi: 10.1016/B978-0-323-85781-9.00015-4
|
| 9 |
Lisa Christiansson, Stina Söderlund, Emma Svensson, Satu Mustjoki, Mats Bengtsson, Bengt Simonsson, Ulla Olsson-Strömberg, Angelica S. I. Loskog, Gobardhan Das. Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia. PLoS ONE 2013; 8(1): e55818 doi: 10.1371/journal.pone.0055818
|
| 10 |
丽葶 黄. The Role of MDSCs in Digestive System Tumors and Research Progress in Targeted Therapy. Advances in Clinical Medicine 2024; 14(09): 925 doi: 10.12677/acm.2024.1492548
|
| 11 |
M.E. Kavanagh, K.E. O’Sullivan, C. O’Hanlon, J.N. O’Sullivan, J. Lysaght, J.V. Reynolds. The esophagitis to adenocarcinoma sequence; the role of inflammation. Cancer Letters 2014; 345(2): 182 doi: 10.1016/j.canlet.2013.08.017
|
| 12 |
E W Lin, T A Karakasheva, P D Hicks, A J Bass, A K Rustgi. The tumor microenvironment in esophageal cancer. Oncogene 2016; 35(41): 5337 doi: 10.1038/onc.2016.34
|
| 13 |
Martin Borgmann, Michael Quante. Impact of the Tumor Microenvironment for Esophageal Tumor Development—An Opportunity for Prevention?. Cancers 2022; 14(9): 2246 doi: 10.3390/cancers14092246
|
| 14 |
Prince Amoah Barnie, Pan Zhang, Hongxiang Lv, Dan Wang, Xiaolian Su, Zhaoliang Su, Huaxi Xu. Myeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disorders. Experimental and Therapeutic Medicine 2017; 13(2): 378 doi: 10.3892/etm.2016.4018
|
| 15 |
Ya‐Wen Lo, Alan Yueh‐Luen Lee, Yi‐Ching Liu, Hui‐Hsin Ko, Hsin‐Hui Peng, Hsiang‐Chieh Lee, Pei‐Yao Pan, Chun‐Pin Chiang, Shih‐Jung Cheng. β‐glucan therapy converts the inhibition of myeloid‐derived suppressor cells in oral cancer patients. Oral Diseases 2022; 28(6): 1484 doi: 10.1111/odi.13827
|
| 16 |
Masoud H. Manjili, Xiang-Yang Wang, Scott Abrams. Evolution of Our Understanding of Myeloid Regulatory Cells: From MDSCs to Mregs. Frontiers in Immunology 2014; 5 doi: 10.3389/fimmu.2014.00303
|
| 17 |
Cirino Botta, Annamaria Gullà , Pierpaolo Correale, Pierosandro Tagliaferri, Pierfrancesco Tassone. Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities. Frontiers in Oncology 2014; 4 doi: 10.3389/fonc.2014.00348
|
| 18 |
Hiroshi Katoh, Masahiko Watanabe, Analía Trevani. Myeloid‐Derived Suppressor Cells and Therapeutic Strategies in Cancer. Mediators of Inflammation 2015; 2015(1) doi: 10.1155/2015/159269
|
| 19 |
Michael R Olin, Walter Low, David H McKenna, Stephen J Haines, Tambra Dahlheimer, David Nascene, Michael P Gustafson, Allan B Dietz, H Brent Clark, Wei Chen, Bruce Blazar, John R Ohlfest, Christopher Moertel. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4+IL17+ response. Journal for ImmunoTherapy of Cancer 2014; 2(1) doi: 10.1186/2051-1426-2-4
|
| 20 |
Jingwei Jiang, Weijian Guo, Xiaohua Liang. Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. Human Immunology 2014; 75(11): 1128 doi: 10.1016/j.humimm.2014.09.025
|
| 21 |
Mohamed Labib Salem, Abdel-Aziz A. Zidan, Mohamed Attia, Randa E. EL-Naggar, Mohamed Nassef, Abdel Raouf Abou El-Azm, Hasan El-Bate, Mohamed Yussif, Sohaila Galal, Mohamed Abo Senna, Maha El Demellawy. IFN-α-based treatment of patients with chronic HCV show increased levels of cells with myeloid-derived suppressor cell phenotype and of IDO and NOS. Immunopharmacology and Immunotoxicology 2017; 39(4): 188 doi: 10.1080/08923973.2017.1320670
|
| 22 |
Eric Jou, Natasha Chaudhury, Fizza Nasim. Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment. Exploration of Targeted Anti-tumor Therapy 2024; 5(1): 187 doi: 10.37349/etat.2024.00212
|
| 23 |
Xiao-Jun Zhang, Yan Yu, He-Ping Zhao, Lei Guo, Kun Dai, Jing Lv. Mechanisms of tumor immunosuppressive microenvironment formation in esophageal cancer. World Journal of Gastroenterology 2024; 30(16): 2195-2208 doi: 10.3748/wjg.v30.i16.2195
|
| 24 |
Sunanda Rajkumari, Jaspreet Singh, Usha Agrawal, Sandeep Agrawal. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives. International Immunopharmacology 2024; 142: 112949 doi: 10.1016/j.intimp.2024.112949
|